Selective expression of phosphoribosylpyrophosphate synthetase superactivity in human lymphoblast lines
- PMID: 2414323
- PMCID: PMC424156
- DOI: 10.1172/JCI112151
Selective expression of phosphoribosylpyrophosphate synthetase superactivity in human lymphoblast lines
Abstract
Phenotypic expression of 5-phosphoribosyl 1-pyrophosphate (PRPP) synthetase superactivity was examined in lymphoblast lines derived from six unrelated male patients. Fibroblasts from these individuals have increased rates of PRPP and purine nucleotide synthesis and express four classes of kinetic derangement underlying enzyme superactivity: increased maximal reaction velocity (catalytic defect); inhibitor resistance (regulatory defect); increased substrate affinity (substrate binding defect); and combined catalytic and regulatory defects. Lymphoblast lines from three patients with catalytic defects and from three normal individuals were indistinguishable with respect to enzyme activities, PRPP concentrations and generation, and rates of purine synthesis. Enzyme in lymphoblasts from a patient with combined defects also showed normal maximal reaction velocity but expressed purine nucleotide inhibitor resistance. A second regulatory defect and a substrate binding defect were also demonstrable in lymphoblasts and were identical to the enzyme defects in fibroblasts from the respective patients. Regulatory and substrate binding defects in lymphoblasts were accompanied by increased rates of PRPP and purine nucleotide synthesis. Among explanations for selective expression of enzyme superactivity, reduced concentrations of catalytically superactive enzymes seemed unlikely: immunoreactive PRPP synthetase was comparable in normal-derived and patient-derived cells. Activation of normal enzyme in transformed lymphocytes was also unlikely because absolute specific activities of lymphoblast PRPP synthetases corresponded to those of normal fibroblast and erythrocyte enzymes. Abnormal electrophoretic mobilities and thermal stabilities, identified in certain catalytically superactive fibroblast PRPP synthetases, were not found in the corresponding lymphoblast enzymes. Thus, lymphoblast PRPP synthetases from patients with catalytic superactivity appeared to differ structurally and functionally from their fibroblast counterparts.
Similar articles
-
Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate.J Lab Clin Med. 1982 Apr;99(4):495-511. J Lab Clin Med. 1982. PMID: 6174658
-
Phosphoribosylpyrophosphate synthetase superactivity. A study of five patients with catalytic defects in the enzyme.Arthritis Rheum. 1986 Jul;29(7):880-8. doi: 10.1002/art.1780290710. Arthritis Rheum. 1986. PMID: 3017368
-
Human phosphoribosylpyrophosphate synthetase: radioimmunochemical quantitation in erythrocytes and fibroblasts.J Lab Clin Med. 1984 Jul;104(1):96-109. J Lab Clin Med. 1984. PMID: 6330252
-
[PRPP synthetase superactivity].Nihon Rinsho. 1996 Dec;54(12):3309-14. Nihon Rinsho. 1996. PMID: 8976111 Review. Japanese.
-
The PRPP synthetase spectrum: what does it demonstrate about nucleotide syndromes?Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1129-39. doi: 10.1080/15257770.2011.591747. Nucleosides Nucleotides Nucleic Acids. 2011. PMID: 22132967 Review.
Cited by
-
Host protein PRPS2 interact with the non-structural protein p17 of Avian Reovirus and promote viral replication.Poult Sci. 2025 Jan;104(1):104582. doi: 10.1016/j.psj.2024.104582. Epub 2024 Nov 28. Poult Sci. 2025. PMID: 39631276 Free PMC article.
-
The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity.J Clin Invest. 1995 Nov;96(5):2133-41. doi: 10.1172/JCI118267. J Clin Invest. 1995. PMID: 7593598 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical